Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
about
Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.Detection of Aberrant TERT Promoter Methylation by Combined Bisulfite Restriction Enzyme Analysis for Cancer Diagnosis.Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy
P2860
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
@en
type
label
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
@en
prefLabel
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
@en
P2093
P2860
P356
P1476
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS
@en
P2093
A John Barrett
Bipin N Savani
Bogdan Dumitriu
Caroline R Cantilena
Danielle M Townsley
Katayoun Rezvani
Keyvan Keyvanfar
Minoo Battiwalla
Neal S Young
Neil Dunavin
P2860
P304
P356
10.1111/BJH.14244
P407
P50
P577
2016-07-19T00:00:00Z